Sponsored Links
| BioCryst Presents New Analyses Of BCX4208 Phase 2 Studies In Patients With Gout At The Annual European Congress Of Rheumatology |
 |
 |
 |
| Medical News - Gout | |||
|
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today presented positive data from its two completed, randomized, double-blind, placebo-controlled Phase 2 studies of BCX4208 in patients with gout at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism (EULAR) in London, U.K... Read more: Gout News From Medical News Today
|